icIL1Ra

icIL1Ra, short for intracellular interleukin-1 receptor antagonist, refers to intracellular isoforms of the IL-1 receptor antagonist produced from the IL1RN gene through alternative transcription and splicing. Unlike the secreted form, icIL-1Ra lacks a signal peptide and is not typically released from the cell, instead localizing to the cytoplasm and, in some contexts, the nucleus. This intracellular localization distinguishes it from sIL-1Ra, which functions as a circulating inhibitor of IL-1 signaling.

The proposed role of icIL-1Ra is to modulate IL-1–driven signaling within cells. It is thought to interact with intracellular components of the IL-1 signaling axis, potentially dampening inflammatory gene expression. The precise mechanisms and targets of icIL-1Ra are not as well defined as those of the secreted form, and its activity appears to be context-dependent, varying by cell type and physiological conditions.

Expression of icIL-1Ra isoforms has been reported in barrier tissues such as the skin, as well as in other cell types, where levels can be influenced by proinflammatory stimuli like IL-1 and TNF. The biological significance of icIL-1Ra is an area of active investigation, with interest in its contributions to tissue differentiation, wound healing, and localized regulation of inflammation.

Because icIL-1Ra biology is less comprehensively characterized than the secreted IL-1 receptor antagonist, its involvement in inflammatory diseases or cancer remains under study. Some research suggests altered icIL-1Ra expression in tissues under inflammatory conditions, highlighting potential therapeutic implications for targeting intracellular IL-1 signaling pathways.

See also: Interleukin-1 receptor antagonist, IL1RN.